Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers.

[1]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[2]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[3]  K. Blennow,et al.  Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients , 2003, Experimental Neurology.

[4]  J. Koenigsknecht-Talboo,et al.  Microglial Phagocytosis Induced by Fibrillar β-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines , 2005, The Journal of Neuroscience.

[5]  L. Provinciali,et al.  Platelet Amyloid Precursor Protein Isoform Expression in Alzheimer's Disease: Evidence for Peripheral Marker , 2011, International journal of immunopathology and pharmacology.

[6]  A. Simon,et al.  Characterization of plasma β‐secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease , 2012, Journal of neuroscience research.

[7]  P. Lewczuk,et al.  The sortilin‐related receptor SORL1 and the amyloid cascade: a possible explanation for the concurrent elevation of CSF soluble APPα and APPβ in Alzheimer's disease , 2010, International journal of geriatric psychiatry.

[8]  K. Malpass.  Alzheimer disease: A novel biomarker to detect early-stage Alzheimer disease , 2011, Nature Reviews Neurology.

[9]  A. Kurz,et al.  Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[10]  J. Stockley,et al.  Understanding BACE1: essential protease for amyloid-β production in Alzheimer’s disease , 2008, Cellular and Molecular Life Sciences.

[11]  F. Bouwman,et al.  Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. , 2006, Clinical chemistry.

[12]  A. Drzezga,et al.  Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature. , 2013, Journal of Alzheimer's disease : JAD.

[13]  Y. Qian,et al.  Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer's disease , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[14]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[15]  A. Kurz,et al.  Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer's disease , 2013, Translational Psychiatry.

[16]  E. Siemers.  How can we recognize “disease modification” effects? , 2009, The journal of nutrition, health & aging.

[17]  B. Allinquant,et al.  Functions of Aβ, sAPPα and sAPPβ : similarities and differences , 2012, Journal of neurochemistry.

[18]  J. Witton,et al.  The functional neurophysiology of the amyloid precursor protein (APP) processing pathway , 2010, Neuropharmacology.

[19]  F. Jessen,et al.  Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[20]  A. Simon,et al.  Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects. , 2008, Clinical biochemistry.

[21]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[22]  Y. Stern.  Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.

[23]  K. Blennow,et al.  Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease , 2012, NeuroMolecular Medicine.

[24]  Nick C. Fox,et al.  Biomarkers for Alzheimer's disease therapeutic trials , 2011, Progress in Neurobiology.

[25]  A. Kurz,et al.  Head circumference, apolipoprotein E genotype and cognition in the Bavarian School Sisters Study , 2012, European Psychiatry.

[26]  V. Lee,et al.  Effects of TNFα-Converting Enzyme Inhibition on Amyloid β Production and APP Processing In Vitro and In Vivo , 2008, The Journal of Neuroscience.

[27]  J. O'Brien,et al.  PET imaging of brain amyloid in dementia: a review , 2011, International journal of geriatric psychiatry.

[28]  C. Brayne,et al.  Epidemiological neuropathology: the MRC Cognitive Function and Aging Study experience. , 2011, Journal of Alzheimer's disease : JAD.

[29]  P. Gil,et al.  Processing of the Platelet Amyloid Precursor Protein in the Mild Cognitive Impairment (MCI) , 2013, Neurochemical Research.

[30]  R. Vassar.  BACE1: the beta-secretase enzyme in Alzheimer's disease. , 2004, Journal of molecular neuroscience : MN.

[31]  H. Hampel,et al.  Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[32]  A. Kurz,et al.  Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid , 2012, Alzheimer's & Dementia.

[33]  Dennis W. Dickson,et al.  Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau) , 2011, Journal of Molecular Neuroscience.

[34]  M. Staufenbiel,et al.  Amyloid‐β protein (Aβ) Glu11 is the major β‐secretase site of β‐site amyloid‐β precursor protein‐cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis , 2013, The European journal of neuroscience.

[35]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[36]  Dong Han,et al.  Diagnostic accuracy of 18F‐FDG and 11C‐PIB‐PET for prediction of short‐term conversion to Alzheimer’s disease in subjects with mild cognitive impairment , 2012, International journal of clinical practice.

[37]  Hans Förstl,et al.  Kognitive Reservekapazität und ihre Bedeutung für Auftreten und Verlauf der Demenz , 2010, Der Nervenarzt.

[38]  A. Kurz,et al.  β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau , 2013, Alzheimer's & Dementia.

[39]  G. Mead,et al.  Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia , 2013, Alzheimer's & Dementia.

[40]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.

[41]  W. M. van der Flier,et al.  BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. , 2010, Journal of Alzheimer's disease : JAD.

[42]  Leslie M. Shaw,et al.  Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium , 2013, Alzheimer's & Dementia.

[43]  K. Blennow,et al.  O3-02-06: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer's disease , 2008, Alzheimer's & Dementia.

[44]  S. Todd,et al.  Expression and activity of β-site amyloid precursor protein cleaving enzyme in Alzheimer's disease , 2005 .

[45]  Florian Auer,et al.  White matter hyperintensities predict amyloid increase in Alzheimer's disease , 2012, Neurobiology of Aging.

[46]  M. Wolfe,et al.  Tumor Necrosis Factor-α, Interleukin-1β, and Interferon-γ Stimulate γ-Secretase-mediated Cleavage of Amyloid Precursor Protein through a JNK-dependent MAPK Pathway* , 2004, Journal of Biological Chemistry.

[47]  P. Sachdev,et al.  American Journal of Epidemiology Original Contribution Cognitive Lifestyle and Long-term Risk of Dementia and Survival after Diagnosis in a Multicenter Population-based Cohort , 2022 .

[48]  K. Blennow,et al.  P3-069: Increased CSF-BACE1 activity is associated with APOE-ϵ4 genotype in subjects with mild cognitive impairment and Alzheimer's disease , 2008, Alzheimer's & Dementia.

[49]  D. Craig,et al.  Elevated Platelet β-Secretase Activity in Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[50]  K. Blennow,et al.  Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease , 2011, Molecular Neurodegeneration.

[51]  L. Grinberg,et al.  Neuropathologic features associated with Alzheimer disease diagnosis , 2011, Neurology.

[52]  F. Jessen,et al.  Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study , 2010, Molecular Psychiatry.

[53]  G. Schellenberg,et al.  Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease , 2011, Neurobiology of Aging.

[54]  K. Blennow,et al.  Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[55]  N. Bark,et al.  Platelet alpha- and beta- secretase activities are not significantly affected by dementia or mild cognitive impairment in Swedish patients. , 2010, Current Alzheimer research.

[56]  G. McKhann.  Changing concepts of Alzheimer disease. , 2011, JAMA.

[57]  R. Shin,et al.  Novel α-secretase cleavage of Alzheimer's amyloid β precursor protein in the endoplasmic reticulum of COS7 cells , 2005, Neuroscience Letters.

[58]  J. Ringman,et al.  Conformation-Dependent Oligomers in Cerebrospinal Fluid of Presymptomatic Familial Alzheimer's Disease Mutation Carriers , 2012, Dementia and Geriatric Cognitive Disorders Extra.

[59]  P. Falkai,et al.  New lexicon and criteria for the diagnosis of Alzheimer's disease , 2011, The Lancet Neurology.

[60]  Anand Viswanathan,et al.  Cerebral amyloid angiopathy in the elderly , 2011, Annals of neurology.

[61]  R. Doms,et al.  Protein Kinase C-dependent α-Secretase Competes with β-Secretase for Cleavage of Amyloid-β Precursor Protein in the Trans-Golgi Network* , 2000, The Journal of Biological Chemistry.

[62]  D. Craig,et al.  Platelet β-secretase activity is increased in Alzheimer's disease , 2008, Neurobiology of Aging.

[63]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[64]  Hans Förstl,et al.  CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease , 2011, Neurology.

[65]  Anne Corbett,et al.  Alzheimer's disease , 2011, The Lancet.

[66]  K. Blennow,et al.  Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease , 2013, Brain Research.

[67]  K. Blennow,et al.  Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. , 2010, Archives of neurology.

[68]  O. Hurko,et al.  The Uses of Biomarkers in Drug Development , 2009, Annals of the New York Academy of Sciences.

[69]  O. Lopez.  Mild Cognitive Impairment , 2013, Continuum.

[70]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[71]  A. Simon,et al.  In Vivo β-Secretase 1 Inhibition Leads to Brain Aβ Lowering and Increased α-Secretase Processing of Amyloid Precursor Protein without Effect on Neuregulin-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[72]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[73]  S. Sparber,et al.  Dopamine concentrations in the brainstem-mesencephalon of active rats as compared with passive rats. , 1970, Neuropharmacology.

[74]  M. Mattson,et al.  An Overview of APP Processing Enzymes and Products , 2010, NeuroMolecular Medicine.

[75]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[76]  C. Jack,et al.  Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.

[77]  G. Weskamp,et al.  Mice Lacking the Metalloprotease-Disintegrin MDC9 (ADAM9) Have No Evident Major Abnormalities during Development or Adult Life , 2002, Molecular and Cellular Biology.

[78]  A. Drzezga,et al.  Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.

[79]  Karl Herholz,et al.  Clinical amyloid imaging in Alzheimer's disease , 2011, The Lancet Neurology.

[80]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[81]  B. Hyman,et al.  Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.

[82]  O. Lopez,et al.  Biomarkers in Alzheimer’s Disease , 2011, Front. Neur..

[83]  J. Mortimer.  The Nun Study: risk factors for pathology and clinical-pathologic correlations. , 2012, Current Alzheimer research.

[84]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[85]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[86]  N. Bohnen,et al.  Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature , 2012, The Journal of Nuclear Medicine.

[87]  E. Godaux,et al.  A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. , 2004, The Journal of clinical investigation.

[88]  W. M. van der Flier,et al.  A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease , 2009, Annals of clinical biochemistry.

[89]  K. Blennow,et al.  Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. , 2008, Brain : a journal of neurology.

[90]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[91]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[92]  D. Selkoe.  The molecular pathology of Alzheimer's disease , 1991, Neuron.

[93]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[94]  E. Kremmer,et al.  ADAM10 is the physiologically relevant, constitutive α‐secretase of the amyloid precursor protein in primary neurons , 2010, The EMBO journal.

[95]  T. Kusaka,et al.  Transporters in the brain endothelial barrier. , 2010, Current medicinal chemistry.

[96]  Stefan J. Teipel,et al.  Levels of β-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment , 2007 .

[97]  E. Peskind,et al.  S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic α-Secretase Activity Acts via Selective Promotion of ADAM-10 , 2009, PloS one.

[98]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[99]  A. Simon,et al.  Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex , 2011, Journal of neuroscience research.

[100]  K. Blennow,et al.  BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease , 2010, Molecular Neurodegeneration.

[101]  Asher Mullard.  Sting of Alzheimer's failures offset by upcoming prevention trials , 2012, Nature Reviews Drug Discovery.

[102]  Nick C Fox,et al.  Brain imaging in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[103]  Sean D Sullivan,et al.  Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[104]  Junxia Xie,et al.  Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer's disease patients of Northern Han Chinese descent. , 2013, Current Alzheimer research.

[105]  K. Blennow,et al.  Fluid biomarkers in Alzheimer’s disease – current concepts , 2013, Molecular Neurodegeneration.

[106]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[107]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[108]  L. Ferrucci,et al.  Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques , 2012, Acta Neuropathologica.

[109]  E. Kojro,et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 , 2001, Proceedings of the National Academy of Sciences of the United States of America.